在肥胖的孕妇中补充抗氧化微量营养素:一个随机对照试验
Sarbattama Sen1,2,3, Sara Cherkerzian4,5, Mary Herlihy5,6
1Department of Pediatric Newborn Medicine, Brigham and Women's Hospital, Boston, MA, USA. Ssen2@bwh.harvard.edu.
International journal of obesity (2005)
|February 23, 2024
概括
在肥胖的孕妇中,高剂量的抗氧化维生素增加了维生素B6水平,但没有影响炎症或氧化应激标志物. 这表明补充策略可能需要调整以获得最佳结果.
科学领域:
- 产科和妇科 产科和妇科
- 营养科学 营养科学
- 孕产妇和胎儿医学 孕产妇和胎儿医学
背景情况:
- 怀孕期间的肥胖与增加的孕产妇发病率和不利的儿童健康结果有关.
- 孕产妇的炎症是这些负面健康影响的潜在原因之一.
- 抗氧化微量营养素可能在减轻这些风险方面发挥作用.
研究的目的:
- 调查是否高剂量的抗氧化微量营养素在肥胖的孕妇可以增加维生素度.
- 为了确定抗氧化微量营养素摄入量增加对怀孕期间炎症和氧化应激的影响.
主要方法:
- 一个双盲,随机对照试验,涉及128名孕妇,BMI≥30kg/m2.
- 参与者接受了标准的产前维生素加上高剂量的抗氧化剂补充剂或安慰剂.
- 在多个时间点收集血液和尿液样本,以测量微量营养素水平,炎症标志物和氧化应激生物标志物.
主要成果:
- 与对照组相比,干预组的维生素B6度明显高.
- 两组之间没有观察到维生素C,维生素E或叶酸水平的显著差异.
- 补充剂没有导致炎症或氧化应激标志物的显著变化.
- 干预组和对照组之间,孕产妇和新生儿的临床结果没有差异.
结论:
- 虽然更高的抗氧化剂维生素补充剂增加了肥胖的孕妇的维生素B6水平,但它没有影响炎症或氧化应激的关键标志物.
- 观察到的效果可能会受到补充剂中使用的特定剂量或微量营养素类型的影响.
- 需要进一步的研究,以优化抗氧化剂补充策略,为肥胖的孕妇.
相关概念视频
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...